Randomised controlled trial of Amalaki Eye drop in comparison with Olopatadine 0.1 percent eye drop in the management of Vataj Abhishyanda (Allergic Conjunctivitis). - Nil

Start Date01 Nov 2024

Sponsor / Collaborator-

IRCT20240614062122N1

/ RecruitingPhase 2IIT

Comparison effect of Olopatadine %0.2 cream with Fluocinolone %0.025 cream in the treatment of hand eczema in patients

Start Date06 Jul 2024

Sponsor / Collaborator-

IRCT20150426021944N5

/ RecruitingPhase 3IIT

Comparing the efficacy of a combination of Mometasone and Olopatadine sprays versus Mometasone spray in children with allergic rhinitis

Start Date19 Jun 2024

Sponsor / Collaborator-

100 Clinical Results associated with Olopatadine Hydrochloride

100 Translational Medicine associated with Olopatadine Hydrochloride

100 Patents (Medical) associated with Olopatadine Hydrochloride

409

Literatures (Medical) associated with Olopatadine Hydrochloride

01 Feb 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Implantation of impressive chromatographic and built-in UV spectrophotometry approaches for sustainable Estimation of olopatadine and mometasone in pharmaceuticals; eco-scale and BAGI applications

Article

Author: Salem, Yomna A ; Elsabour, Samah A ; El-Masry, Amal A ; Emad F Abbas, Ahmed

The development of analytical methods that adhere to the principles of sustainable green chemistry is essential in the modern scientific arena. This research presents two novel methods for the concurrent quantification of olopatadine (OLO) and mometasone (MOM), targeting sustainable green chemistry principles in their raw materials, dosage forms and combined nasal spray formulations. The first method is a rapid isocratic high-performance liquid chromatography (HPLC) that achieves excellent resolution within 4 min, with retention times of 2.37 ± 0.1 min for OLO and 4.05 ± 0.1 min for MOM. It features optimal sensitivity, with detection limits of 0.13 µg/mL for OLO and 0.03 µg/mL for MOM. It utilizes a cyano column with an isocratic mobile phase of acetonitrile and 0.1 M OPA (50: 50, v/v), making it accessible to standard laboratory equipment. The second method is UV-visible spectrophotometry, which includes first-order derivative measurement (D1) and ratio derivative spectra (RDS) methods. These spectroscopic approaches provide linear response range of 0.2-20.0 µg/mL for OLO and 4.0-40.0 µg/mL for MOM, respectively serving as cost-effective alternatives for labs with limited resources. Validation results show high accuracy (98-102 %) and precision (RSD < 2 %). Green assessments using Eco-Scale indicate scores of 86 for HPLC and 100 for spectrophotometry, while the "blueness" concept via BAGI demonstrates strong sustainability with scores of 87.5 and 90. These methods effectively quantify OLO and MOM in their raw materials, different formulations and combined nasal spray, providing a sustainable and reliable approach for pharmaceutical analysis. This work is the first green assessment for the determination of OLO and MOM in pure drug and in the pharmaceutical formulations using less hazard solvent and simple technique.

09 Jan 2025·Journal of Medicinal Chemistry

Probing the Histamine H₁ Receptor Binding Site to Explore Ligand Binding Kinetics

Article

Author: Bosma, Reggie ; Vischer, Henry F. ; Kuhne, Sebastiaan ; Leurs, Rob ; de Esch, Iwan J. P. ; Riemens, Rick ; Stroet, Marc C. M. ; de Graaf, Chris ; Wijtmans, Maikel ; Kooistra, Albert J.

Analysis of structure-kinetic relationships (SKR) can contribute to an improved understanding of receptor-ligand interactions. Here, fragment 1 (4-(2-benzylphenoxy)-1-methylpiperidine) was used in different fragment growing approaches to mimic the putative binding mode of the long residence time (RT) ligands olopatadine, acrivastine, and levocetirizine at the histamine H₁ receptor (H₁R). SKR analyses reveal that introduction of a carboxylic acid moiety can increase RT at H₁R up to 11-fold. Ligand efficiency (LE) decreases upon the introduction of the negatively charged group, whereas kinetic efficiency (KE) increases up to 8.5-fold. The olopatadine/acrivastine mimics give up to 15-fold differences in the RT, while the levocetirizine mimics afford similar RTs with only a 3-fold difference. Therefore, the levocetirizine mimics are less sensitive to structural changes. This study illustrates that for H₁R, there are several ways to increase RT but the different strategies differ significantly in SKR.

01 Jan 2025·Journal of Veterinary Medical Science

Comparing the effectiveness of four antihistamines with olopatadine in healthy Thoroughbred horses

Article

Author: OHTA, Minoru ; KURODA, Taisuke ; TAMURA, Norihisa ; IKEDA, Yasuhiko ; MITA, Hiroshi

We compared the antihistamine effect of four new antihistamines with olopatadine, which is used to treat equine allergic diseases. Six healthy Thoroughbred horses received oral doses of olopatadine (50 mg), levocetirizine (50 mg), bilastine (200 mg), rupatadine (100 mg), and desloratadine (50 mg) at >2-week intervals. The effects were investigated by measurement of the wheal area induced by histamine intradermal injection, and inhibition rate was compared with positive and negative controls. The maximum wheal inhibition rate (mean ± SD) of olopatadine (85.3% ± 7.7%) was significantly higher than those of bilastine (51.1% ± 11.8%), rupatadine (55.3% ± 6.6%), and desloratadine (59.8% ± 6.4%), but not levocetirizine (85.4% ± 8.0%). Levocetirizine is expected to have a high antihistamine effect on horses.

News (Medical) associated with Olopatadine Hydrochloride

12 Sep 2024

·www.inotekcorp.com

Effective Non-Prescription Pink Eye Drops for Nocturnal Lagophthalmos Management – Benefits, Usage, and User Testimonials

Nocturnal lagophthalmos is a condition characterized by the inability to fully close the eyelids during sleep. This can lead to various eye health issues, including dryness, irritation, and increased risk of infections. Individuals with nocturnal lagophthalmos may experience symptoms such as discomfort, redness, and excessive tearing upon waking up. The condition can result in compromised eye protection and lubrication, which are essential for maintaining optimal eye health. Research has shown that nocturnal lagophthalmos can be linked to certain medical conditions, such as Bell’s palsy, facial nerve damage, or anatomical abnormalities. It is important for individuals experiencing symptoms of nocturnal lagophthalmos to consult with an eye care professional for proper diagnosis and management. Furthermore, untreated nocturnal lagophthalmos can lead to more serious complications, including corneal abrasions, ulcers, or infections. Therefore, early detection and appropriate treatment are crucial in preventing potential long-term damage to the eyes. By understanding the nature of nocturnal lagophthalmos and its impact on eye health, individuals can take proactive steps to address the condition and protect their vision. For more information on nocturnal lagophthalmos, please visit the American Academy of Ophthalmology website. When it comes to managing nocturnal lagophthalmos, using non-prescription pink eye drops can be highly beneficial in alleviating symptoms and promoting eye health. These over-the-counter solutions are designed to provide relief from inflammation and irritation, which are common issues associated with nocturnal lagophthalmos. Here are some key reasons why incorporating non-prescription pink eye drops into your treatment regimen is essential: Relieves Dryness: Nocturnal lagophthalmos can lead to dry eyes due to inadequate moisture during sleep. Pink eye drops help lubricate the eyes, reducing dryness and discomfort. Reduces Inflammation: Inflammation is a common symptom of lagophthalmos, and non-prescription pink eye drops containing anti-inflammatory properties can help minimize redness and swelling. Promotes Comfort: By providing immediate relief from discomfort and irritation, pink eye drops can enhance overall comfort levels and support better sleep quality. Prevents Infections: Properly formulated non-prescription pink eye drops can help create a protective barrier against potential infections, safeguarding your eye health. It is essential to choose high-quality non-prescription pink eye drops that are specifically designed for treating nocturnal lagophthalmos. Look for products that are gentle on the eyes, free from harsh chemicals, and suitable for long-term use. “For individuals experiencing nocturnal lagophthalmos, incorporating non-prescription pink eye drops into their nightly routine can significantly improve eye comfort and reduce symptoms of dryness and inflammation.” $35.66 $65.17 $29.00 $64.80 Non-steroid eye drops are commonly used to address inflammation in the eyes, including conditions like nocturnal lagophthalmos. These eye drops work by targeting the underlying inflammatory processes that can worsen symptoms and impact eye health. When selecting non-steroid eye drops for managing inflammation associated with nocturnal lagophthalmos, it is essential to choose products that are specifically formulated for ocular use. These eye drops typically contain active ingredients such as ketotifen or olopatadine, which help alleviate inflammation and reduce discomfort. Studies have shown that non-steroid eye drops can effectively reduce inflammation in the eyes without the side effects commonly associated with steroid-based medications. These eye drops are usually safe for long-term use and can provide symptomatic relief for individuals with conditions like nocturnal lagophthalmos. It is important to follow the recommended usage instructions provided by the manufacturer or healthcare provider when using non-steroid eye drops. Generally, these eye drops are administered as one to two drops in the affected eye(s) a few times a day or as needed to manage symptoms. It is crucial to consult with an eye care professional before starting any new eye drop regimen, especially if you have underlying health conditions or are taking other medications. Your eye doctor can recommend the most suitable non-steroid eye drops for your specific needs and ensure they are safe and effective for managing inflammation associated with nocturnal lagophthalmos. Non-prescription antibiotic eye drops play a vital role in managing nocturnal lagophthalmos by helping to prevent and treat secondary infections that can occur due to the condition. Using these eye drops can aid in reducing the risk of complications and supporting overall eye health. Antibiotic eye drops are specifically designed to target and eliminate harmful bacteria that may enter the eyes during sleep when the eyelids do not fully close. By applying these drops before bedtime, individuals with nocturnal lagophthalmos can create a protective barrier against potential infections, such as conjunctivitis (pink eye) or keratitis. One of the key benefits of non-prescription antibiotic eye drops is their convenience and ease of use. They are readily available over the counter, allowing individuals to access them without a prescription. This accessibility makes it simpler for those with nocturnal lagophthalmos to incorporate the drops into their nightly eye care routine. Moreover, non-prescription antibiotic eye drops are generally well-tolerated and safe for regular use. They are formulated to be gentle on the eyes while effectively combating bacteria, helping to maintain ocular health and comfort. It is essential to follow the instructions provided with the eye drops to ensure proper application and maximize their effectiveness. In a recent survey conducted among individuals with nocturnal lagophthalmos, over 80% reported experiencing a reduction in eye irritation and redness after using non-prescription antibiotic eye drops regularly. This positive feedback highlights the beneficial effects of incorporating these drops into a comprehensive eye care regimen for managing the condition. It is recommended to consult with an eye care professional before starting any new eye drop regimen, including non-prescription antibiotic drops, to ensure they are suitable for individual needs and do not interact with any existing medications. By utilizing non-prescription antibiotic eye drops as part of a proactive eye care approach, individuals with nocturnal lagophthalmos can help safeguard their eye health and minimize the risk of infections. Non-steroid eye drops play a crucial role in managing the symptoms of nocturnal lagophthalmos. These eye drops aim to reduce inflammation and provide relief from discomfort associated with the condition. Here’s how non-steroid eye drops can help alleviate the symptoms of nocturnal lagophthalmos: Reduction of Inflammation: Non-steroid eye drops contain ingredients that help reduce inflammation in the eyes. By targeting the inflammatory response, these eye drops can help alleviate redness, swelling, and irritation caused by nocturnal lagophthalmos. Pain Relief: Non-steroid eye drops can provide pain relief for individuals experiencing discomfort due to nocturnal lagophthalmos. The soothing properties of these eye drops can help alleviate soreness and sensitivity in the eyes. Improved Eye Moisture: Nocturnal lagophthalmos can lead to dry eyes, making them prone to irritation and discomfort. Non-steroid eye drops can help improve eye moisture levels, keeping the eyes lubricated and reducing dryness. “Using non-steroid eye drops has significantly improved my comfort level during the night. I no longer wake up with dry, irritated eyes, thanks to the soothing effects of these eye drops.” – Sarah K., Nocturnal Lagophthalmos Patient Research has shown that non-steroid eye drops are effective in managing the symptoms of various eye conditions, including nocturnal lagophthalmos. These eye drops are gentle yet powerful in providing relief and reducing inflammation in the eyes. When selecting non-steroid eye drops for nocturnal lagophthalmos, it is essential to choose a formula that is gentle, preservative-free, and suitable for long-term use. Consult with your healthcare provider or eye care specialist to determine the best non-steroid eye drops for your specific needs. Many individuals suffering from nocturnal lagophthalmos have reported positive experiences with non-prescription pink eye drops in managing their condition. Here are some testimonials highlighting the effectiveness of these eye drops: “I have been using non-prescription pink eye drops for my nocturnal lagophthalmos for a few weeks now, and I have noticed a significant improvement in my eye health. The drops help keep my eyes moist throughout the night and reduce the discomfort I used to experience.” – John D. “I was skeptical about using non-prescription eye drops at first, but after trying them for my nocturnal lagophthalmos, I am impressed with the results. My eyes feel more comfortable, and I wake up with fewer dryness symptoms.” – Sarah L. These testimonials demonstrate that non-prescription pink eye drops can be a valuable tool in managing the symptoms of nocturnal lagophthalmos and improving overall eye health. If you are experiencing similar issues, consider incorporating these eye drops into your nightly routine. When choosing non-prescription eye drops to manage nocturnal lagophthalmos, it’s essential to consider several factors to ensure effective results. Here are some tips to help you select the right eye drops: Consultation with a healthcare professional: Before purchasing any non-prescription eye drops, consult with an eye care specialist or healthcare provider to get guidance on the best options for managing your condition. Ingredient suitability: Look for eye drops specifically designed for dry eyes and nighttime eye care. Ingredients such as hyaluronic acid, glycerin, and vitamin E can help lubricate and protect the eyes while you sleep. Packaging and formulation: Opt for eye drops that come in single-dose vials or preservative-free packaging to reduce the risk of contamination and ensure the freshness of the product. Effectiveness and user reviews: Research and read user reviews of the eye drops to gauge their effectiveness in managing nocturnal lagophthalmos. Look for positive feedback and testimonials from users who have found relief from their symptoms. Allergy considerations: If you have known allergies or sensitivities to certain ingredients, make sure to review the label of the eye drops and avoid products that may trigger an allergic reaction. By following these tips and making an informed decision when selecting non-prescription eye drops for managing nocturnal lagophthalmos, you can ensure that you are using a product that is safe, effective, and tailored to your specific needs.

01 Feb 2024

·www.biospace.com

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1st Experienced executives bring extensive track record in products for retinal and ophthalmology diseases MELBOURNE, Australia, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development, and Fang Li, Ph.D. RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer, Frederic Guerard, PharmD, MS, and will join the Opthea Executive Management Team. “It is my great pleasure to welcome two ophthalmology experts, Dr. Clark and Dr. Li, to the Company as we prepare for the next stage in our growth and work towards advancing the development of sozinibercept (OPT-302),” said Dr. Guerard. “Their past contributions to the development and registration of ophthalmology therapies such as IZERVAY™, BEOVU®, and EYLEA®, will be instrumental to the potential success of our lead program investigating sozinibercept, currently in two Phase 3 pivotal trials.” Dr. Clark shared, “I am thrilled to join Opthea as we prepare to complete patient enrollment in the pivotal Phase 3 clinical program for sozinibercept in the first half of 2024. The majority of my career has been dedicated to the clinical development of novel therapies for retinal diseases. Sozinibercept could be the first new drug for wet age-related macular degeneration (AMD) in more than 15 years, with the potential to deliver superior visual gains when administered in combination with standard of care therapy. I look forward to contributing to bringing this novel product candidate to patients with serious retinal disease.” Dr. Li commented, “As we work towards the potential release of topline results for our Phase 3 program in mid-2025, I am excited to apply my expertise to support the development and execution of our regulatory strategy and potential filings for sozinibercept in the U.S. and other markets. I look forward to the opportunity to bring Opthea’s innovative potential medicine through the regulatory process for the benefit of patients with retinal diseases.” Julie Clark, MD, MS With more than 15 years of experience in ophthalmology medical and clinical development, Dr. Clark brings expertise in both early and late-stage programs, regulatory submissions, and approvals. Her contributions include substantial support for the approval and launches of retinal therapies such as EYLEA®, JETREA® and BEOVU®. In Dr. Clark’s most recent position as Vice President Clinical Development at IVERIC bio, Inc., An Astellas Company, she oversaw the development program leading to the August 2023 U.S. Food and Drug Administration (FDA) approval of IZERVAY™, a complement inhibitor approved for the treatment of geographic atrophy secondary to age-related macular degeneration. Dr. Clark previously served as Chief Medical Officer at Adverum Biotechnologies Inc, where she played a crucial role in developing intravitreal delivered gene therapy for retinal diseases. Dr. Clark is a graduate of Wake Forest University and Wake Forest University School of Medicine in Winston-Salem, NC, U.S. Fang Li, PhD, RAC Dr. Li brings over 30 years of expertise in drug development and more than 20 years in regulatory affairs experience. Her experience spans various domains including small molecules, biologics, gene therapy, over-the-counter products, in-vitro diagnostic products and medical devices, with a specific focus on ophthalmology. She has held key roles at prominent ophthalmology companies such as Novartis AG, Alcon Inc., and Bausch + Lomb Corporation. Dr. Li's extensive background includes significant involvement in health authority interactions, U.S. FDA advisory committee meeting preparation and the establishment and leadership of regulatory teams. She has a proven track record of success in obtaining product approvals in the U.S. and other regions. Throughout her career, Dr. Li has played a pivotal role in leading numerous FDA drug approvals, specifically contributing to the approval of ophthalmology products like JETREA®, LOTEMAX® Ointment, SYSTANE® COMPLETE. She has also contributed to the development and registration of other ophthalmology drug products such as BEOVU®, PAZEO®, LOTEMAX® GEL, BESIVANCE®, and VYZULTA®. Fang holds a PhD in Medicinal Chemistry from China Pharmaceutical University, China. About Opthea Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including neovascular (wet) age-related macular degeneration (wet AMD). Opthea’s lead product candidate sozinibercept is being evaluated in two pivotal Phase 3 clinical trials (ShORe, NCT04757610, and COAST, NCT04757636) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care. To learn more, visit and follow us on X and LinkedIn. Inherent risks of Investment in Biotechnology Companies There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments. Forward-looking Statements This ASX announcement contains certain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The words “expect”, “believe,” “should”, “could”, “may”, “will”, “plan” and other similar expressions are intended to identify forward-looking statements. Forward-looking statements in this ASX announcement include statements regarding expectations on the outcomes of Opthea’s Phase 3 clinical trials of sozinibercept, the potential for sozinibercept as a combination therapy to be the first therapy to achieve superior visual outcomes over anti-VEGF-A monotherapy and improve vision outcomes for patients with wet AMD, the expected timing for completion of enrollment for the Phase 3 studies and topline data, the market opportunity for sozinibercept, and the future performance of Opthea. Forward-looking statements, opinions and estimates provided in this ASX announcement are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current conditions. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. They involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Opthea and its directors and management and may involve significant elements of subjective judgment and assumptions as to future events that may or may not be correct. These statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to future capital requirements, the development, testing, production, marketing and sale of drug treatments, regulatory risk and potential loss of regulatory approvals, ongoing clinical studies to demonstrate sozinibercept safety, tolerability and therapeutic efficacy, additional analysis of data from Opthea’s Phase 3 clinical trials, timing of completion of Phase 3 clinical trial patient enrollment and clinical research organization and labor costs, intellectual property protections, and other factors that are of a general nature which may affect the future operating and financial performance of the Company including risk factors set forth in Opthea’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 28, 2023 and other future filings with the SEC. Actual results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Subject to any continuing obligations under applicable law or any relevant ASX listing rules, Opthea disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this ASX announcement to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based, except as otherwise required by applicable law. Authorized for release to ASX by Frederic Guerard, CEO Company & Media Enquiries: Rudi Michelson Monsoon Communications Tel: +61 (0) 3 9620 3333 Investor Enquiries PJ Kelleher LifeSci Advisors Email: pkelleher@lifesciadvisors.com Join our email database to receive program updates: Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web:

Phase 3Executive ChangeDrug Approval

26 Oct 2023

·www.prnewswire.com

Nanoscope Therapeutics Strengthens Research and Development Leadership with Appointment of Najam Sharif, PhD, DSc.

DALLAS, Oct. 26, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced the appointment of Najam Sharif, PhD, DSc, a veteran in drug/device discovery and development, as Vice President of Global Research and Development. "We are delighted to welcome Naj to the Nanoscope team," said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope. "His extensive experience in ophthalmology and pharmaceutical drug discovery and development is a natural fit for our organization, and we look forward to drawing on his clinical and regulatory expertise in particular at this pivotal time for MCO-010." "I am honored to join Nanoscope, a company that I see as transformative in the field of ophthalmology. As their lead asset, MCO-010, advances toward FDA approval, I look forward to the opportunity to positively impact the lives of people living with inherited retinal diseases, and to bring treatment options to a population for which there are no established cures," said Dr. Sharif. Dr. Naj Sharif brings over three decades of experience in pharmaceutical drug/device discovery and development to Nanoscope, including specialized expertise in ophthalmology and neuroscience. Throughout his career, he contributed to the discovery and development of several FDA-approved commercial drugs, including anti-glaucoma agent Travatan® and anti-allergic/inflammatory drugs such as Patanol® /Pataday® and Emedine®. In addition, Dr. Sharif was instrumental in guiding three drugs through to FDA approvals: Simbrinza® for glaucoma, IZBA® for the treatment of ocular hypertension and glaucoma, and PAZEO™ for the treatment ocular allergies. Most recently, Dr. Sharif served as Vice President, Global Biomedical Sciences & Head of Glaucoma and Neuroprotection at Santen, where he managed the company's Clinical Sciences, Data Sciences, and Biometrics departments, and where he also established and directed Global Alliances & External Research activities. Prior to this, he held positions related to R&D and regulatory affairs at Alcon Research-Novartis, Synaptic Pharmaceutical Corp, and Syntex Pharma / Roche Pharmaceutical Corp. He is widely published with an extensive number of peer-reviewed publications, edited books and holds multiple patents for mitigation of neurological and ophthalmic diseases. He has been an invited organizer, chairman and speaker at multiple national and international conferences. In addition to his professional experience, Dr. Sharif has served on numerous boards and committees. Dr. Sharif is an elected Fellow of multiple learned societies such as Association for Research in Vision and Ophthalmology, Association for Ocular Pharmacology and Therapeutics and British Pharmacological Society. Currently he serves on the Scientific Advisory Board of the Glaucoma Foundation and as an adjunct professor for the Duke-NUS Medical School in Singapore, and Institute of Ophthalmology at University College London. He is the recipient of several honors, including the Ernst H. Barany prize for "Outstanding Contributions to Ocular Pharmacology", the first and inaugural "Dr. Roger Vogel Award" for Pharmaceutical Research, and the Sir James Black Award for "Contributions to Drug Discovery". Dr. Sharif received a PhD in neuroscience, DSc (by thesis) in ophthalmology, and dual bachelor's degree in physiology and biochemistry from the University of Southampton (UK). About Nanoscope Therapeutics Inc. Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company's lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy. Investor Contact: Argot Partners 212-600-1902 [email protected] SOURCE Nanoscope Therapeutics

Phase 2Orphan DrugClinical ResultExecutive ChangeFast Track

100 Deals associated with Olopatadine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01192	Olopatadine Hydrochloride	R01AC08 S01GX09	DB00768

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Allergic rhinoconjunctivitis	JP	Novartis Pharma KK	26 Jul 2006
Seasonal allergic conjunctivitis	AU	Novartis Pharmaceuticals Australia Pty Ltd.	16 May 2002
Seasonal allergic conjunctivitis	NO	Novartis Europharm Ltd.	16 May 2002
Seasonal allergic conjunctivitis	LI	Novartis Europharm Ltd.	16 May 2002
Seasonal allergic conjunctivitis	IS	Novartis Europharm Ltd.	16 May 2002
Seasonal allergic conjunctivitis	EU	Novartis Europharm Ltd.	16 May 2002
Pruritus	JP	Kyowa Kirin Co., Ltd.	22 Dec 2000
Rhinitis, Allergic	JP	Kyowa Kirin Co., Ltd.	22 Dec 2000
Urticaria	JP	Kyowa Kirin Co., Ltd.	22 Dec 2000
Conjunctivitis, Allergic	US	Alcon Laboratories, Inc.	18 Dec 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Urticaria	NDA/BLA	CN	Anhui Sihuan Kebao Pharmaceutical Co., Ltd.	30 Sep 2024
Acute conjunctivitis	Phase 3	-	Alcon Research Ltd.	01 Oct 2009
Conjunctivitis, Allergic	Phase 3	-	Alcon Research Ltd.	01 Oct 2009
Rhinitis, Allergic	Phase 3	US	Alcon Research Ltd.	01 Oct 2008
Rhinitis, Allergic, Seasonal	Phase 3	US	Novartis Pharmaceuticals Corp.	15 Apr 2008
Rhinitis, Allergic, Perennial	Phase 3	US	Alcon Research Ltd.	01 Dec 2006
Rhinoconjunctivitis	Phase 3	-	Alcon Research Ltd.	18 Apr 2006
Seasonal allergic conjunctivitis	Phase 3	-	Alcon Research Ltd.	18 Apr 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02478398 (CTgov)	Phase 3	Rhinitis, Allergic, Seasonal \| Asthma \| Allergic rhinoconjunctivitis	1,025	Mometasone furoate monohydrate+Self-injectable epinephrine+Olopatadine+Albuterol+Loratadine+Short ragweed pollen allergen extract (Short Ragweed Pollen Allergen Extract)	hzcoedwnno(sgxrkjvsxv) = oswkodhukm eamyvskmqv (skolxezynd, fnmhfpjxez - ehgqymhzwb) View more	-	09 Jul 2019
				Placebo+Mometasone furoate monohydrate+Self-injectable epinephrine+Olopatadine+Albuterol+Loratadine (Placebo)	hzcoedwnno(sgxrkjvsxv) = zvjenyplmk eamyvskmqv (skolxezynd, yyjbndvzri - tqmkfjthly) View more
APAO2019	Not Applicable	Vernal Keratoconjunctivitis	96	Olopatadine 0.1%	(rdjrtzfexl) = hzevtqkmfj xhmbhxymup (spyftehgsd )	Positive	06 Mar 2019
				Sodium Cromoglycate 2%	(rdjrtzfexl) = terdguyfei xhmbhxymup (spyftehgsd )
NCT00609128 (CTgov)	Not Applicable	Conjunctivitis, Allergic \| Lacerations	21	olopatadine	iwdkuqbjum(povykvsrbz) = jprunotmhp nkbslhpzmx (sapwykxexx, apncjtoucf - biuhflvllk) View more	-	20 Sep 2018
ARVO2016	Not Applicable	Anaphylaxis	111	Lastacaft	(rwmrpopwzf) = tmavwvtenu ussizoxbxm (hfyflaqzfn )	-	01 May 2016
				Pataday	(rwmrpopwzf) = epwajdbebh ussizoxbxm (hfyflaqzfn )
NCT01363700 (CTgov)	Phase 3	Conjunctivitis, Allergic	87	Epinastine (DE-114) (Epinastine (DE-114) Ophthalmic Solution)	cqfhkmgoaq(kbbcnsmtqu) = hpsmfwazgl swoahnhioi (cfxjfnfvvw, eidoldqrpg - bhzsqyuzsf) View more	-	05 Nov 2014
				Placebo (Placebo Ophthalmic Solution)	cqfhkmgoaq(kbbcnsmtqu) = drhzypqvzg swoahnhioi (cfxjfnfvvw, nnvduzygsy - hglusbwqny) View more
NCT01470118 \| NCT01732757 (Pubmed \| Adv Ther)	Phase 4	Conjunctivitis, Allergic	284	Alcaftadine 0.25%	eepwhcawdn(ucyndbshhc) = kitkyrioos kajmhzxahn (xvpepmmpxf )	Positive	01 Oct 2014
				Olopatadine 0.2%	eepwhcawdn(ucyndbshhc) = jxmnpqhkhp kajmhzxahn (xvpepmmpxf )
NCT01697969 (CTgov)	Phase 4	Conjunctivitis, Allergic	17	Olopatadine hydrochloride (Left Eye)	nmtffgfxcr(otyprhytpp) = pmpokksgbv ufzohqadjf (vcnedsikow, octhzyaudd - rpukrgcdso) View more	-	18 Aug 2014
				Olopatadine hydrochloride (Right Eye)	nmtffgfxcr(otyprhytpp) = chfvpzjwbi ufzohqadjf (vcnedsikow, bqwzczfuig - ajwkbibnnf) View more
NCT01743027 (CTgov)	Phase 3	Conjunctivitis, Allergic	902	AL-4943A ophthalmic solution (AL-4943A)	rrxoxdoghn(ydbmrtxfqz) = aukxbmxqgj ustdayqqjx (fbdvxxuzst, wdcxclxhzc - vevnngclrt) View more	-	11 Aug 2014
				Olopatadine hydrochloride ophthalmic solution, 0.2% (PATADAY)	rrxoxdoghn(ydbmrtxfqz) = xrloozkhwp ustdayqqjx (fbdvxxuzst, owvolbnncc - mgzlsrvgoa) View more
NCT01698814 (CTgov)	Phase 3	Conjunctivitis, Allergic	518	AL-4943A Ophthalmic Solution (AL-4943A)	(yrsgcccsor) = uuwfokezus uevedjgjvc (enmnfwcbvg, hidyfjfibf - dgqermizwg) View more	-	28 Feb 2014
				AL-4943A Ophthalmic Solution (AL-4943A Vehicle)	(yrsgcccsor) = mnvhurjquz uevedjgjvc (enmnfwcbvg, adkiyncdcl - dbqqcyltjv) View more
NCT01732757 (CTgov)	Phase 4	Acute conjunctivitis \| Conjunctivitis, Allergic	157	Alcaftadine 0.25% (Lastacaft®)	wqmjxiocwk(rayhnkkuhb) = gcyzvyrlxp yuwnjtpchd (qzoebwcazx, cgnqgvnfrg - vhbwpomyit) View more	-	14 Jan 2014
				Olopatadine 0.2% (Pataday™)	wqmjxiocwk(rayhnkkuhb) = neormorwsd yuwnjtpchd (qzoebwcazx, gztfeaakhc - sdckagezap) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Olopatadine Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation